A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors

Abstract excerpt

Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly BRCA alterations, display enhanced sensitivity to these agents because of synthetic lethality induced by PARP inhibitors. These agents have...

Topics

Join the communities discussing this publication.

• BRCA gene mutations in cancer
• Ovarian cancer diagnosis and treatment
• PARP inhibition in cancer therapy